Adapted from Truveta; Chart: Axios Visuals
Shortages of commonly prescribed drugs for attention deficit hyperactivity disorder have stretched on for nearly 18 months, with no clear end in sight for many Americans who've found it difficult if not impossible to get the treatments.
Why it matters: As demand for stimulants like Adderall and Vyvanse soared, the fill rate for such prescriptions has dropped more than 10% in two years, according to a new analysis from health analytics firm Truveta.
